Axogen Inc (FRA:LT3)
€ 6.25 -0.05 (-0.76%) Market Cap: 276.97 Mil Enterprise Value: 324.91 Mil PE Ratio: 0 PB Ratio: 3.19 GF Score: 63/100

AxoGen Inc at Cantor Fitzgerald Global Healthcare Conference Transcript

Oct 02, 2019 / 05:15PM GMT
Release Date Price: €10.2 (-10.53%)
Craig Bijou
Cantor Fitzgerald - Analyst

Hello, good afternoon. I am Craig Bijou, a medical device analyst here at Cantor. It's a pleasure to have Axogen and their CEO, Karen Zaderej. So, Karen, let me just pass it over to you. There may be some that aren't familiar or as familiar with Axogen, so just give us an overall background of the Company and what you guys do.

Karen Zaderej
AxoGen, Inc. - Chairman, CEO & President

Sure. Thanks, Craig. Well, Axogen is focused in the area of peripheral nerve repair. And everything that we work with is helping surgeons with injuries to nerves which can happen in lots of ways. Basically we help surgeons when a nerve is cut, how do you restore continuity so that patient gets back sensation and movement and does that without pain. I will talk about pain in a little bit.

We also help surgeons when nerves are compressed. So, when nerves are compressed it alters the signal conduction and can cause muscle weakness, pain and loss of sensation. And so, we have an array of surgical products that surgeons use to try and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot